Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, Phase Ib study

Journal of Clinical Oncology

Volumn 35, Issue 19, 2017, Pages 2117-2124

  Apolo, Andrea B ^a   Infante, Jeffrey R ^a   Balmanoukian, Ani ^a   Patel, Manish R ^a   Wang, Ding ^a   Kelly, Karen ^a   Mega, Anthony E ^a   Britten, Carolyn D ^a   Ravaud, Alain ^a   Mita, Alain C ^a   Safran, Howard ^a   Stinchcombe, Thomas E ^a   Srdanov, Marko ^a   Gelb, Arnold B ^a   Schlichting, Michael ^a   Chin, Kevin ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; AVELUMAB; CISPLATIN; CREATINE KINASE; HEMOGLOBIN; IMMUNOGLOBULIN G1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; MONOCLONAL ANTIBODY;

ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLADDER CARCINOMA; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLUSHING; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; KIDNEY PELVIS CARCINOMA; LEG CRAMP; LIVER METASTASIS; LUNG METASTASIS; MACULOPAPULAR RASH; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RIGOR; SIDE EFFECT; SWEATING; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URETER CARCINOMA; URETHRA CARCINOMA; UVEITIS; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 85020609662     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.6795     Document Type: Article

References (29)

1. Ervik M, Lam F, Ferlay J., et al: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2016. http://gco.iarc.fr/today
2. Kaufman D, Raghavan D, Carducci M., et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927, 2000
3. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
4. Apolo AB, Ostrovnaya I, Halabi S., et al: Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst 105:499-503, 2013
5. Vaughn DJ, Broome CM, Hussain M, et al: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20:937-940, 2002
6. Galsky MD, Mironov S, Iasonos A., et al: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25:265-270, 2007
7. McCaffrey JA, Hilton S, Mazumdar M., et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853-1857, 1997
8. Bellmunt J, Théodore C, Demkov T., et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
9. Postow MA, Callahan MK, Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982, 2015
10. TheraCys (BCG live), intravesical [package insert]. Toronto, Ontario, Canada: Sanofi Pasteur Limited; 2013.
11. Fuge O, Vasdev N, Allchorne P., et al: Immunotherapy for bladder cancer. Res Rep Urol 7:65-79, 2015
12. Alexandrov LB, Nik-Zainal S, Wedge D.C., et al: Signatures of mutational processes in human cancer. Nature 500:415-421, 2013
13. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
14. Chen DS, Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39: 1-10, 2013
15. Powles T, Eder JP, Fine G.D., et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
16. Rosenberg JE, Hoffman-Censits J, Powles T., et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
17. TECENTRIQ: (atezolizumab) injection [package insert]. South San Francisco, CA: Genentech, Inc; 2016.
18. McDaniel AS, Alva A, Zhan T., et al: Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma. Eur Urol Focus 1: 265-268, 2016
19. Jiang L, Zhao Z, Jiang S., et al: Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. Immunol Res 62:316-324, 2015
20. Heery CR, O'Sullivan Coyne GH, Madan RA, et al: Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol 32:5s, 2014 (suppl; abstr 3064)
21. Grenga I, Donahue RN, Lepone L.M., et al: A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology 5:e83, 2016
22. Vandeveer AJ, Fallon JK, Tighe R, et al: Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res 4: 452-462, 2016
23. Boyerinas B, Jochems C, Fantini M., et al: Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3: 1148-1157, 2015
24. Lepone LM, Donahue RN, Farsaci B, et al: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells. Cancer Res 75:15 Suppl, 2015 (abstr 1316)
25. Eisenhauer EA, Therasse P, Bogaerts J., et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
26. Agarwal N, Bellmunt J, Maughan B.L., et al: Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer 12: 130-137, 2014
27. Massard C, Gordon MS, Sharma S, et al: Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34:3119-3125, 2016
28. Sharma P, Callahan MK, Bono P, et al: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, openlabel, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17:1590-1598, 2016
29. Plimack ER, Bellmunt J, Gupta S., et al: Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet Oncol 18:212-220, 2017